{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:47:54Z","timestamp":1795034874343,"version":"4.10.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5387-9","type":"journal-article","created":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T07:03:27Z","timestamp":1551337407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms"],"prefix":"10.1186","volume":"19","author":[{"given":"Tarinee","family":"Rungjirajittranon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1262-2005","authenticated-orcid":false,"given":"Weerapat","family":"Owattanapanich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patompong","family":"Ungprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noppadol","family":"Siritanaratkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theera","family":"Ruchutrakool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"issue":"22","key":"5387_CR1","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1056\/NEJMra1406186","volume":"376","author":"JL Spivak","year":"2017","unstructured":"Spivak JL. Myeloproliferative neoplasms. N Engl J Med. 2017;376(22):2168\u201381.","journal-title":"N Engl J Med"},{"issue":"20","key":"5387_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood."},{"issue":"10","key":"5387_CR3","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s00277-017-3099-2","volume":"96","author":"D Kc","year":"2017","unstructured":"Kc D, Falchi L, Verstovsek S. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review. Ann Hematol. 2017;96(10):1595\u2013604.","journal-title":"Ann Hematol"},{"issue":"16","key":"5387_CR4","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313 quiz 615.","journal-title":"Blood"},{"key":"5387_CR5","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","volume":"2012","author":"A Falanga","year":"2012","unstructured":"Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Program. 2012;2012:571\u201381.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"5387_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s11899-017-0400-3","volume":"12","author":"K Martin","year":"2017","unstructured":"Martin K. Risk factors for and management of MPN-associated bleeding and thrombosis. Curr Hematol Malignancy Rep. 2017;12(5):389\u201396.","journal-title":"Curr Hematol Malignancy Rep"},{"issue":"3","key":"5387_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6","volume":"66","author":"P Fenaux","year":"1990","unstructured":"Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66(3):549\u201356.","journal-title":"Cancer"},{"issue":"11","key":"5387_CR8","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","volume":"67","author":"M Colombi","year":"1991","unstructured":"Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia: a retrospective study of 103 patients. Cancer. 1991;67(11):2926\u201330.","journal-title":"Cancer"},{"issue":"2","key":"5387_CR9","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/sj.leu.2401270","volume":"13","author":"C Besses","year":"1999","unstructured":"Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda JC, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13(2):150\u20134.","journal-title":"Leukemia"},{"issue":"3","key":"5387_CR10","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1046\/j.1365-2141.1999.01399.x","volume":"105","author":"A Manoharan","year":"1999","unstructured":"Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105(3):618\u201325.","journal-title":"Br J Haematol"},{"issue":"2","key":"5387_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","volume":"65","author":"MK Jensen","year":"2000","unstructured":"Jensen MK, de Nully BP, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol. 2000;65(2):132\u20139.","journal-title":"Eur J Haematol"},{"issue":"10","key":"5387_CR12","first-page":"1011","volume":"85","author":"F Passamonti","year":"2000","unstructured":"Passamonti F, Brusamolino E, Lazzarino M, Barate C, Klersy C, Orlandi E, et al. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients. Haematologica. 2000;85(10):1011\u20138.","journal-title":"Haematologica"},{"issue":"22","key":"5387_CR13","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1001\/archinte.165.22.2651","volume":"165","author":"CS Chim","year":"2005","unstructured":"Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med. 2005;165(22):2651\u20138.","journal-title":"Arch Intern Med"},{"issue":"10","key":"5387_CR14","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","volume":"23","author":"R Marchioli","year":"2005","unstructured":"Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224\u201332.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5387_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/sj.leu.2404048","volume":"20","author":"F Cervantes","year":"2006","unstructured":"Cervantes F, Alvarez-Larran A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia. 2006;20(1):55\u201360.","journal-title":"Leukemia"},{"issue":"2","key":"5387_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4065\/81.2.159","volume":"81","author":"AP Wolanskyj","year":"2006","unstructured":"Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81(2):159\u201366.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"5387_CR17","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","volume":"109","author":"A Carobbio","year":"2007","unstructured":"Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109(6):2310\u20133.","journal-title":"Blood"},{"issue":"3","key":"5387_CR18","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","volume":"110","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110(3):840\u20136.","journal-title":"Blood"},{"issue":"3","key":"5387_CR19","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1160\/TH08-06-0396","volume":"101","author":"SM Bang","year":"2009","unstructured":"Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, et al. Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation. Thromb Haemost. 2009;101(3):547\u201351.","journal-title":"Thromb Haemost"},{"issue":"4","key":"5387_CR20","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115(4):778\u201382.","journal-title":"Blood"},{"issue":"10","key":"5387_CR21","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","volume":"95","author":"MA Elliott","year":"2010","unstructured":"Elliott MA, Pardanani A, Lasho TL, Schwager SM, Tefferi A. Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked. Haematologica. 2010;95(10):1788\u201391.","journal-title":"Haematologica"},{"issue":"8","key":"5387_CR22","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s00277-010-1154-3","volume":"90","author":"F Palandri","year":"2011","unstructured":"Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90(8):933\u20138.","journal-title":"Ann Hematol"},{"issue":"7","key":"5387_CR23","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1002\/ajh.23217","volume":"87","author":"V Buxhofer-Ausch","year":"2012","unstructured":"Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early\/prefibrotic myelofibrosis: an international study of 264 patients. Am J Hematol. 2012;87(7):669\u201372.","journal-title":"Am J Hematol"},{"issue":"4","key":"5387_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/leu.2011.258","volume":"26","author":"G Finazzi","year":"2012","unstructured":"Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"5387_CR25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.medcli.2014.04.029","volume":"144","author":"A Angona","year":"2015","unstructured":"Angona A, Alvarez-Larran A, Bellosillo B, Martinez-Aviles L, Garcia-Pallarols F, Longaron R, et al. Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients. Med Clin (Barc). 2015;144(6):247\u201353.","journal-title":"Med Clin (Barc)"},{"issue":"5","key":"5387_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ejim.2015.03.009","volume":"26","author":"A Enblom","year":"2015","unstructured":"Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J, et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 2015;26(5):344\u20137.","journal-title":"Eur J Intern Med"},{"issue":"5","key":"5387_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.thromres.2015.02.023","volume":"135","author":"Y Lim","year":"2015","unstructured":"Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, et al. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135(5):846\u201351.","journal-title":"Thromb Res"},{"issue":"12","key":"5387_CR28","doi-asserted-by":"publisher","first-page":"5013","DOI":"10.7314\/APJCP.2015.16.12.5013","volume":"16","author":"B Duangnapasatit","year":"2015","unstructured":"Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, et al. Clinical manifestations and risk factors for complications of Philadelphia chromosome-negative myeloproliferative neoplasms. Asian Pac J Cancer Prev. 2015;16(12):5013\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"5387_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"5387_CR30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41408-017-0035-6","volume":"7","author":"S Cerquozzi","year":"2017","unstructured":"Cerquozzi S, Barraco D, Lasho T, Finke C, Hanson CA, Ketterling RP, et al. Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. Blood Cancer J. 2017;7(12):662.","journal-title":"Blood Cancer J"},{"issue":"6","key":"5387_CR31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/ejh.12873","volume":"98","author":"K Abdulkarim","year":"2017","unstructured":"Abdulkarim K, Samuelsson J, Johansson P, Andreasson B. Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN registry. Eur J Haematol. 2017;98(6):577\u201383.","journal-title":"Eur J Haematol"},{"issue":"1","key":"5387_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4274\/tjh.2016.0005","volume":"34","author":"N Soyer","year":"2017","unstructured":"Soyer N, Haznedaroglu IC, Comert M, Cekdemir D, Yilmaz M, Unal A, et al. Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms. Turk J Haematol. 2017;34(1):27\u201333.","journal-title":"Turk J Haematol"},{"issue":"8","key":"5387_CR33","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","volume":"96","author":"I Bertozzi","year":"2017","unstructured":"Bertozzi I, Bogoni G, Biagetti G, Duner E, Lombardi AM, Fabris F, et al. Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden. Ann Hematol. 2017;96(8):1297\u2013302.","journal-title":"Ann Hematol"},{"key":"5387_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.leukres.2018.03.013","volume":"69","author":"D Zhou","year":"2018","unstructured":"Zhou D, Chen W, Cheng H, Qiao JL, Zhu LL, Li ZY, et al. Clinico-hematological profile and thrombotic\/hemorrhagic events in 150 chinese patients with essential thrombocythemia. Leuk Res. 2018;69:1\u20136.","journal-title":"Leuk Res"},{"issue":"9","key":"5387_CR35","doi-asserted-by":"publisher","first-page":"8450","DOI":"10.18632\/oncotarget.23879","volume":"9","author":"S Hintermair","year":"2018","unstructured":"Hintermair S, Zwickl-Traxler E, Pecherstorfer M, Singer J. Evaluation of vascular events in patients with myeloproliferative syndromes and mutations of either the januskinase-2 or calreticulin gene at the university hospital Krems from 2008 to 2015. Oncotarget. 2018;9(9):8450\u201362.","journal-title":"Oncotarget"},{"key":"5387_CR36","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:2535.","journal-title":"BMJ"},{"key":"5387_CR37","doi-asserted-by":"crossref","unstructured":"Mathes T, Kuss O. A comparison of methods for meta-analysis of a small number of studies with binary outcomes. Res Synth Methods. 2018;9:1\u201316.","DOI":"10.1002\/jrsm.1296"},{"issue":"7414","key":"5387_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360.","journal-title":"BMJ"},{"issue":"1","key":"5387_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1055\/s-0037-1617146","volume":"30","author":"J Xu","year":"2010","unstructured":"Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010;30(1):5\u20136 8-9.","journal-title":"Hamostaseologie"},{"issue":"3","key":"5387_CR40","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s11239-017-1528-7","volume":"44","author":"E Vazquez-Garza","year":"2017","unstructured":"Vazquez-Garza E, Jerjes-Sanchez C, Navarrete A, Joya-Harrison J, Rodriguez D. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J Thromb Thrombolysis. 2017;44(3):377\u201385.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"5387_CR41","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0034-1370794","volume":"40","author":"A Falanga","year":"2014","unstructured":"Falanga A, Marchetti M. Thrombosis in myeloproliferative neoplasms. Semin Thromb Hemost. 2014;40(3):348\u201358.","journal-title":"Semin Thromb Hemost"},{"issue":"5","key":"5387_CR42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00277-016-2621-2","volume":"95","author":"I Appelmann","year":"2016","unstructured":"Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the hemostasis working Party of the German Society of hematology and medical oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH). Ann Hematol. 2016;95(5):707\u201318.","journal-title":"Ann Hematol"},{"issue":"6","key":"5387_CR43","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V68.6.1213.1213","volume":"68","author":"U Budde","year":"1986","unstructured":"Budde U, Dent JA, Berkowitz SD, Ruggeri ZM, Zimmerman TS. Subunit composition of plasma von Willebrand factor in patients with the myeloproliferative syndrome. Blood. 1986;68(6):1213\u20137.","journal-title":"Blood"},{"issue":"1","key":"5387_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/rth2.12064","volume":"2","author":"DA Keesler","year":"2018","unstructured":"Keesler DA, Flood VH. Current issues in diagnosis and treatment of von Willebrand disease. Res Pract Thromb Haemost. 2018;2(1):34\u201341.","journal-title":"Res Pract Thromb Haemost"},{"issue":"3","key":"5387_CR45","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0740-2570(03)00025-X","volume":"20","author":"JW Vardiman","year":"2003","unstructured":"Vardiman JW. Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic\/myeloproliferative diseases. Semin Diagn Pathol. 2003;20(3):154\u201379.","journal-title":"Semin Diagn Pathol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5387-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T19:12:51Z","timestamp":1582830771000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5387"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5387-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]},"assertion":[{"value":"1 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The need for ethics approval by an institutional board review was waived as this study does not directly involve human subjects.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable because this study does not directly involve human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"184"}}